IMR Press / FBL / Special Issues / 1429702478186074114

Vaccine and anti-viral drug development for SARS-CoV2

Submission deadline: 31 May 2022
Special Issue Editors
Sang Heui Seo, MD
College of Veterinary Medicine, Chungnam National University, Daejeon, South Korea
Interests: Pathogenicity; Immune Responses in Influenza Virus; Coronavirus
Special Issue Information

Dear Colleagues,

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as covid-19 still causes tremendous burden on humans. This virus has many variants such as Alpha, Beta, Gamma and Delta. Some variants have the potential for the increased trasnsmissibility, increased virulence, or reduced effectiveness of vaccines against current vaccines.

We need to develop better vaccine for protecting people from being infected from emerging variants SARS-CoV2 and anti-viral drugs to treat humans infected with SARS-CoV2. The goal of this special issue is to publish new approach to vaccines and anti-viral drugs for SARS-CoV2. Interesting researchers are encouraged to submit short reports, and full papers based on animal studies and human clinical trials.

Prof. Sang Heui Seo

 

Guest Editor

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (6 Papers)
Open Access Review
The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
Jie Wang, Qian Zhang, Hongmei Wang, Wenping Gong
Front. Biosci. (Landmark Ed) 2022, 27(5), 157; https://doi.org/10.31083/j.fbl2705157
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
15
Download
34
Views
Open Access Original Research
Potential SARS-CoV-2 nonstructural proteins inhibitors: drugs repurposing with drug-target networks and deep learning
Shayan K. Azmoodeh, Igor F. Tsigelny, Valentina L. Kouznetsova
Front. Biosci. (Landmark Ed) 2022, 27(4), 113; https://doi.org/10.31083/j.fbl2704113
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
34
Download
152
Views
Open Access Original Research
Thymosin-α1 binds with ACE and downregulates the expression of ACE2 in human respiratory epithelia
Yu-Hang Zhang, Wen-Yu Wang, Xiao-Cong Pang, Zhi Wang, ... Yi-Min Cui
Front. Biosci. (Landmark Ed) 2022, 27(2), 48; https://doi.org/10.31083/j.fbl2702048
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
37
Download
105
Views
Open Access Original Research
UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines
Evelyn J. Franco, Kelly L. Warfield, Ashley N. Brown
Front. Biosci. (Landmark Ed) 2022, 27(1), 3; https://doi.org/10.31083/j.fbl2701003
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
34
Download
1
Citations
146
Views
Open Access Article
Heterogeneity in susceptibility to hydroxychloroquine of SARS-CoV-2 isolates
Celine Boschi, Marion Le Bideau, Julien Andreani, Sarah Aherfi, ... Bernard La Scola
Front. Biosci. (Landmark Ed) 2021, 26(12), 1493–1502; https://doi.org/10.52586/5043
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
33
Download
1
Citations
124
Views
Back to top